Maeda M, Kuzuya N, Masuyama Y, Imai Y, Ikeda H
J Clin Endocrinol Metab. 1976 Jul;43(1):10-7. doi: 10.1210/jcem-43-1-10.
Studies were performed on 40 patients with severe primary hypothyroidism, during treatment with varying doses of T4. Therapy was initiated with 50 mug/day and was continued for at least 2 months. Subsequent repeated increases of 25 mug/day were continued for at least 2 months until the serum TSH level was less than 10 muU/ml. Measurements of serum T4 and T3, RT3U, and serum TSH were carried out at monthly intervals. TRH tests were performed after TSH levels of less than 10 muU/ml had been attained and the dose of T4 had been maintained for at least 2 months. In most of the samples obtained during treatment with various doses of T4 (50-175 mug/day), serum T4 concentrations were within the normal range, even when patients were receiving only 50 mug/day of T4; however, approximately 60% of the samples had subnormal T3 concentrations. Fifty per cent of the samples had elevated TSH concentrations despite normal T4 levels, while only 7% of the samples with normal T3, as well as T4, levels had slightly elevated TSH concentrations. Similar relationships were observed between serum TSH and free T4 indices and free T3 indices. Among patients with serum TSH levels of less than 10 muU/ml, none showed subnormal T4 concentrations, while subnormal T3 concentrations were found in some of them. Hyper-response to TRH was noted in patients with subnormal T3 levels, and normal responses were observed in patients with normal T3 and T4 concentrations. These data indicate that, during the treatment of hypothyroidism with T4, 1) normal basal TSH correlates better with normal serum T4 and T3 than with normal T4 alone, 2) the response of TSH to TRH is supranormal in patients with subnormal T3 levels, in spite of normal basal TSH and T4, and 3) the calculated maintenance dose of T4, which is associated with a normal TRH response, is 2.08 mug/day/kg of body weight.
对40例重度原发性甲状腺功能减退患者进行了研究,这些患者接受不同剂量的T4治疗。治疗从每天50微克开始,持续至少2个月。随后每天以25微克的增量重复增加剂量,持续至少2个月,直到血清促甲状腺激素(TSH)水平低于10微单位/毫升。每月测定血清T4、T3、反三碘甲状腺原氨酸摄取率(RT3U)和血清TSH。在TSH水平低于10微单位/毫升且T4剂量维持至少2个月后进行促甲状腺激素释放激素(TRH)试验。在使用不同剂量T4(每天50 - 175微克)治疗期间获得的大多数样本中,即使患者仅接受每天50微克的T4,血清T4浓度仍在正常范围内;然而,约60%的样本T3浓度低于正常水平。尽管T4水平正常,但50%的样本TSH浓度升高,而T3和T4水平均正常的样本中只有7%的TSH浓度略有升高。血清TSH与游离T4指数和游离T3指数之间也观察到类似关系。在血清TSH水平低于10微单位/毫升的患者中,没有发现T4浓度低于正常水平的情况,但其中一些患者的T3浓度低于正常水平。T3水平低于正常的患者对TRH有高反应,而T3和T4浓度正常的患者则观察到正常反应。这些数据表明,在用T4治疗甲状腺功能减退期间,1)正常的基础TSH与正常的血清T4和T3的相关性比仅与正常T4的相关性更好;2)尽管基础TSH和T4正常,但T3水平低于正常的患者中TSH对TRH的反应是超常的;3)与正常TRH反应相关的T4计算维持剂量为每天每千克体重2.08微克。